Blood test to guide treatment for limited cancer spread
Part of Cancer clinical trials.
This trial looks at using a simple blood test (ctDNA) to help guide treatment for people whose cancer has spread to a few places. It may help doctors choose the best local treatment and monitor how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a solid cancer that has spread to other parts of the body.
- You are planning to receive local treatment (like surgery or radiation) for all the sites where the cancer has spread.
- You are at least 18 years old.
- You are able to give blood samples for testing.
- You have not had another type of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study is for people with solid tumors that have spread to a few spots (5 or fewer) in the body. It tests whether using a focused treatment like radiation or ablation on those spots can help control the cancer long-term.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Oligometastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.